BCD-248 is a bispecific monoclonal antibody, an original investigational product for medical use being developed for the treatment of multiple myeloma.

A monoclonal antibody is a protein created by scientists in a laboratory, similar to the natural antibodies of the immune system, designed to bind to a specific target in the human body. A bispecific monoclonal antibody can bind simultaneously to two different targets¹.

BCD-248 specifically binds to the B cell maturation antigen (BCMA) protein expressed on tumor cells and to the CD3 protein on the surface of immune cells. Thus, the antibody binds the tumor cell and the immune cell, which activates the latter and destroys the tumor cells².

In the clinical trial, BCD-248 is administered subcutaneously. The physician-investigator closely monitors the patient’s condition throughout their participation in the study and will take all necessary actions to manage adverse events if they occur. To reduce the risk of adverse reactions, all patients are given antiallergic and antipyretic drugs before the administration of BCD-248.

BCD-248 is one of the drugs in BIOCAD’s clinical development program.

1. Dahlen E., Veitonmaki N., Norlen P. Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother. 2018;6(1):3–17.
2. Shah N., Chari A., Scott E., Mezzi K., Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985–1005.

​This section of the website contains information about about a clinical trial of an unregistered medicinal product.